



Epidemiology of Acute Polyradiculoneuritis at Fann Department of Neurology Dakar, Senegal

Anna Modji Basse, Soumaila Boubacar, Adjaratou Dieynabou Sow, Ngor Side Diagne, Marième Soda Diop, Ndiaga Matar Gaye, Maouly Fall, Ibrahima Mariam Diallo, Ousmane Cisse, Alassane Mamadou Diop, Lala Bouna Seck, Kamadore Touré, Moustapha Ndiaye, Amadou Gallo Diop, Mouhamadou Mansour Ndiaye

Department of Neurology, Fann National Teaching Hospital, Dakar, Senegal

Email address:

basse_anna@yahoo.fr (A. M. Basse)

To cite this article:

Anna Modji Basse, Soumaila Boubacar, Adjaratou Dieynabou Sow, Ngor Side Diagne, Marième Soda Diop, Ndiaga Matar Gaye, Maouly Fall, Ibrahima Mariam Diallo, Ousmane Cisse, Alassane Mamadou Diop, Lala Bouna Seck, Kamadore Touré, Moustapha Ndiaye, Amadou Gallo Diop, Mouhamadou Mansour Ndiaye. Epidemiology of Acute Polyradiculoneuritis at Fann Department of Neurology Dakar, Senegal. *Clinical Neurology and Neuroscience*. Vol. 1, No. 4, 2017, pp. 76-79. doi: 10.11648/j.cnn.20170104.11

Received: February 11, 2017; **Accepted:** April 21, 2017; **Published:** June 28, 2017

Abstract: The acute polyradiculoneuritis (APRN) Guillain Barre Syndrome (GBS) is the most typical case and best documented. In sub Saharan Africa, very few studies are conducted are peripheral neuropathies in general and the APRN in particular. The goal of our was to determine the epidemiological profile of the patients hospitalized in our service and in the diagnosis of APRN was held. We had a retrospective study of descriptive type in Neurology department at the Fann National Teaching hospital in Dakar (Senegal). The software Epi Info6 has been used for the analysis and interpretation of data. A total 2694 patients hospitalized during the period of investigation, 39 patients (27 women and 12 men) were admitted for a GBS and which the diagnosis was retained as such depending on our criteria for inclusion. Thus, the hospital prevalence was 1.44%. The average age was 33.9 years with extremes of 11 and 74. The risk factors were dominated by the context of post-partum (63.6%) and type gastroenteritis infections (29.41%) and flu syndrome (23.5%). Albumino-cytological dissociation in the Cerebrospinal liquid (CSL) was objectified in 10 patients (45.4%) and the electroneuromyogram concluded in a demyelinating form in 48.4%, axonal form for 24% and a mixed form (27.7%). A corticosteroid therapy was administered at 53.4% of the patients. All patients had received a symptomatic and functional rehabilitation. Evolution in two months was marked by motor sequelae at 79.9%. Furthermore, 8 patients (20.5%) were transferred to unit and intensive care including mortality of (10.2%) had been recorded. Acute polyradiculoneuritis or Guillain Barre Syndrome have a professional impact. Primary prevention for reduction of morbidity and mortality attributable to this pathology.

Keywords: Guillain Barre Syndrome, Epidemiology, Dakar

1. Introduction

The acute polyradiculoneuritis are a heterogeneous group of inflammatory diseases of the peripheral nerves which syndrome Guillain bar (GBS) is the most typical and best documented. In sub Saharan Africa, very few studies are conducted are peripheral neuropathies in general and the ANNI in particular. The objective of our study was to determine the epidemiological profile of the patients hospitalized in our department and in the diagnosis of APRN was held.

2. Methods

We had carried a descriptive retrospective study from January 2010 to June 2016, or 3 years and a half, and which was focused on records of 39 patients hospitalized for a GBS In our Neurology department at Fann National hospital in Dakar (Senegal). The data have been collected on a question seeking information of sociodemographic, clinical, paraclinical (biological, electrophysiological), therapeutic and evolutive. The software Epi Info6 has been used for the analysis and interpretation of data.

3. Results

On a workforce 2694 patients hospitalized during the period of investigation, 39 patients (27 women and 12 men) were admitted for a GBS and which the diagnosis was retained as such depending on our criteria for inclusion. Thus, the hospital prevalence was 1.44% with a frequency of 6 cases per year between 2010 and 2016. The average age was 33.9 years with extremes of 11 and 74. The risk factors were dominated by the context of post-partum (63.6%) and type gastroenteritis infections (29.41%) and flu syndrome (23.5%). Clinical prototype table was that of a paralyzing form, to ascending extension (94.7%), rapidly progressive in less than 3 days (71.7%), quadriplegic (89.7%), predominantly proximal (51.2%), hypotonic and hyporeflexia. About the paraclinique, an albumino-cytological dissociation in the CSF was objectified in 10 patients (45.4%) and the electroneuromyogram concluded in a demyelinating form in 48.4%, axonal form for 24% and a mixed form (27.7%). A specific treatment based on Corticoids and adjuvants was administered to 53.4% of the patients. All patients had received a symptomatic and functional rehabilitation. Evolution was marked by 8 transfer in resuscitation unit (20.5%) where 4 deaths (10.2%) were

registered and a rate of sequels to two months of 79.9%.




Figure 1. Distribution of Guillain Barre Syndrome by sex.




Figure 2. Distribution of Guillain Barre Syndrome by age.

Table 1. Annual distribution of Guillain Barre Syndrome.

Years	Absolute frequency	Relative frequency %
2010	04	10,25
2011	05	12,82
2012	03	7,69
2013	08	20,51
2014	07	17,94
2015	06	15,38
30 june 2016	06	15,38
Total	39	100

Table 2. Prodromal events.

Prodromes (Context)	Absolute frequency	Relative frequency %
postpartum	7	63,63
Pelvic surgery	3	27,27
Pregnancy	1	9,1
Total	11	100

Table 3. Interval between infectious events and beginning of the signs.

Delay between infectious events and of unrest.	Absolute frequency	Relative frequency %
Between 1 and 2 weeks	2	11,76
Between 2 and 4 weeks	6	35,29
More than 4 weeks	9	52,94
Total	17	100

4. Discussion

The term GBS Syndrome (GBS) is the most common cause of paralytic neuropathy, acute and relates a number of distinct variants [1]. It's an inflammatory polyneuropathy characterized by a sudden onset, a rapid progression, symmetrical muscle weakness, unstable ambulation and hypo - or areflexia [2, 3]. GBS initially was reported in 1859 by Jean Baptiste Octave Landry de Theizillat through 10 cases of ascending paralysis leading to death in 2 cases [4]. However, the CSL will not be considered before 1891 (Wynter and angioedema) [5]. Its annual incidence is estimated between 0.6 to 4/100 000 [6, 7]. Its annual incidence is estimated between 0.6 to 4/100 000 [6, 7]. It is present in all regions of the world, in all seasons and key as well the child as an adult at any age with it seems a discreet predilection for males (1.5 man for a woman) [8, 9, 10]. In our work, hospital prevalence was 1.44%. and an incidence of 6 cases per year between 2010 and 2016 (Table 1). However, our results show a female (69,23% against 31.7%) (Figure 1) which could be explained by the importance of the circumstances of the occurrence of the syndrome in our region largely due to post-partum, pelvic surgery and pregnancy. Furthermore, all ages are affected by GBS in our study with a predominantly between 30 and 40 years (Figure 2). In its typical form, the SG is manifested by a proximo-distal motor deficit of installation upward and evolves in 3 phases (Extension, plateau and recovery.) Studies show that in 90% of cases it comes form sensitivo-motor of demyelinating [11]. In 2/3 cases the symptoms settle after an infectious episode. The extension phase of the deficit peaked most often in two weeks (60 to 70%). By definition, it does

not exceed four weeks [12, 13, 14, 15]. As in our study, the installation of the deficit was to ascending extension (94.7%), rapidly progressive in less than 3 days (71.7%), quadriplegic (89.7%), predominantly proximal (51.2%). In our study, the symptomatology was preceded by an infectious syndrome dominated followed obstetric infections of digestive infections. Biologically, albumino-cytological dissociation has been replaced by a high CSF protein and enriched antibody anti-ganglioside and anti-proteins antibodies of the nodes of Ranvier [16].

This albimino-cytological dissociation has been found in less than half of our patients (45.4% of cases). Denervation activity (fibrillation, slow potential) translated the occurrence of an axonal damage primitive or secondary to a prolonged demyelination. Electrophysiological anomalies are offset from the signs it is why it can be interesting to repeat the examination when the first electroneuromyogram is not contributory [17]. In practice, the diagnosis of GBS is initially established on clinical data without waiting for the electromyographic study. In our work, the electroneuromyogramme concluded in a demyelinating form in 48.4%, axonal form for 24% and a mixed form (27.7%). The treatment of GBS requires a multidisciplinary approach consisting of general medical care and immunological treatment [1]. Although there is no specific medication for GBS, a number of drugs have been used to target components of the immune response including the intravenous (IV) immunoglobulines and plasma exchange and proven effective in the treatment of the GBS, but oral and intravenous corticosteroids, alone or in combination with IV immunoglobulins or plasmapheresis have not been effective in patients with a GBS [18, 19]. our patients have not benefited from plasmapheresis and immunoglobulins of because of their inaccessibility in our context. However, they all received a corticosteroid to the acute phase. Indeed, some authors have reported the interest of corticosteroids in the treatment of neuropathic pain occurring at the acute GBS when administered [20: 21]; This treatment remains however very little used in practice [22, 23]. Quick relief from pain after intravenous administration of corticosteroids has been reported in a few cases [24]. Functional reduction be considered for patients with a GBS [25, 26, 27]. All our patients had received a functional rehabilitation and symptomatic treatment depending on the case.. Evolution in two months was marked by motor sequelae at 79.9%. This is similar to a Tunisian cohort in which only 1/3 of the sick had a total recovery after an average of 17 months of follow-up [28].

5. Conclusion

Acute polyradiculonevritis are a handicapping with impact socio-occupational illness. Primary prevention of infections in a tropical environment and the provision of therapeutic means to reduce the morbidity and mortality attributable to this pathology.

References

- [1] Susanna Esposito, Maria Roberta Longo. Guillain-Barré syndrom. *Autoimmunity Reviews* 16 (2017) 96–101.
- [2] Ropper A. The Guillain-Barré symptom complex. *N Engl J Med* 1992; 17: 1130–6.
- [3] Schessl J, Luther B, Kirschner J, Mauff G, Korinthenberg R. Infections and vaccinations preceding childhood Guillain-Barré symptom complex: a prospective study. *Eur J Pediatr* 2006; 165: 605–12.
- [4] Landry O. Note sur la paralysie ascendante aiguë. *Gazette Hebdomadaire Méd Chir* 1859; 6: 472–4–486–8.
- [5] Pearce JM. Octave Landry's ascending paralysis and the Landry-Guillain-Barre-Strohl syndrome. *J Neurol Neurosurg Psychiatry* 1997 May; 62 (5): 495–500.
- [6] Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. *Acta Neurol Scand* 2004 Aug; 110 (2): 100–6.
- [7] Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. *Neurology* 2008 Apr 29; 70 (18): 1608–13.
- [8] Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. *Acta Neurol Scand* 2004 Aug; 110 (2): 100–6.
- [9] Hughes RA, Cornblath DR. Guillain-Barre syndrome. *Lancet* 2005 Nov 5; 366 (9497): 1653–66.
- [10] van KR, van Doorn PA, Schmitz PI, Ang CW, van der Meche FG. Mild forms of Guillain-Barre syndrome in an epidemiologic survey in The Netherlands. *Neurology* 2000 Feb 8; 54 (3): 620–5.
- [11] Rees JH, Soudain SE, Gregson NA, Hughes RA. *Campylobacter jejuni* infection and Guillain-Barre syndrome. *N Engl J Med* 1995 Nov 23; 333 (21): 1374–9.
- [12] Ropper AH. The Guillain-Barre syndrome. *N Engl J Med* 1992 Apr 23; 326 (17): 1130–6.
- [13] van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. *Lancet Neurol* 2008 Oct; 7 (10): 939–50.
- [14] Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. *Ann Neurol* 1990; 27 Suppl: S21–S24.
- [15] Winer JB, Hughes RA, Osmond C. A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. *J Neurol Neurosurg Psychiatry* 1988 May; 51 (5): 605–12.
- [16] Alain Créange. L'évolution de la conception de la polyradiculonévrite de Guillain-Barré. *revue neurologique* 173 S (2017) S194–S199.
- [17] Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. *Muscle Nerve*, 1985 Jul; 8 (6): 528–39.
- [18] Pithadia AB, Kakadia N. Guillain-Barré syndrome. *Pharmacol Rep* 2010; 62: 220–32.
- [19] Vitaliti G, Tabatabaie O, Matin N, Ledda C, Pavone P, Lubrano R, Serra A, Di Mauro P, Cocuzza S, Falsaperla R. The usefulness of immunotherapy in pediatric neurodegenerative disorders: a systematic review of literature data. *Hum Vaccin Immunother* 2015; 11: 2749–63.
- [20] CAMBIER J, BRUNET P. (1970). Le syndrome de Guillain et Barré. Paris: Eds JB Ballières et fils; p. 115.
- [21] PARRY GJ. (1993). Guillain-Barré syndrome. New-York; Thieme Medical Publishers, p. 200.
- [22] ROCA B, MENTERO A, SIMON E. (1997). Pain and opioid analgesics in Guillain-Barré syndrome. *Neurology*, 48: 328–331.
- [23] R. Kabore, L. Magy, S. Boukhris, T. Mabrouk, M. Lacoste, J.-M. Vallat. Intérêt de la corticothérapie dans le traitement de la douleur à la phase aiguë du syndrome de Guillain-Barré. *Rev Neurol (Paris)* 2004; 160: 8–9, 821–823.
- [24] SÀNCHEZ-GUERRA M, INFANTE J, PASCUAL J, BERCIAÑO J. (2002). Severe backache in Guillain-Barré syndrome. *Muscle Nerve*, 25: 468.
- [25] Liu J, Wang LN, McNicol ED. Pharmacological treatment for pain in Guillain-Barré syndrome. *Cochrane Database Syst Rev* 2015; 4, CD009950.
- [26] Ruts L, Drenthen J, Jongen JL, Hop WC, Visser GH, Jacobs BC, van Doorn PA, Dutch GBS Study Group. Pain in Guillain-Barré syndrome: a long-term follow-up study. *Neurology* 2010; 75: 1439–47.
- [27] Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet* 2016; 388: 717–27.
- [28] M. A. Gargouri, I. Bouchhima, E. Turki, M. Dammak, M. Imed Miladi, C. Mhiri. Aspects épidémiologiques, cliniques et évolutifs du syndrome de Guillain Barré dans la région de Sfax. *revue neurologique* 170 s (2014) a 33 – a 46 A37.